18F-canagliflozin

**18F-canagliflozin** is a fluorine-18 radiolabeled version of canagliflozin developed as a **PET imaging tracer** to visualize tissue distribution and target engagement of sodium-glucose cotransporter 2 inhibition in vivo. Mechanistically, it retains the pharmacology of canagliflozin as a **selective, reversible inhibitor of sodium/glucose cotransporter 2**, but its intended use is diagnostic rather than therapeutic, enabling assessment of SGLT2 binding and occupancy in tissues such as the renal proximal tubule and potentially cardiac, vascular, and brain tissue. The tracer was developed by **Universitair Medisch Centrum Groningen** and collaborators to study interindividual variability in SGLT2 inhibitor exposure and to support exploratory imaging studies in **chronic kidney disease**, including dialysis populations, as well as prior feasibility work in type 2 diabetes.

Other names

[18F]canagliflozin18F canagliflozin